definiens: means the ( i ) Know - How and ( ii ) Patent Rights, in each case that are Controlled by Alnylam as of the Effective Date, listed on Exhi bit 3, which are comprised of manufacturing technol ogy and other technology . No more than once per calendar ye ar Regulus may request that this definition be expa nded to include any improvements to such Know - How and Paten t Rights listed on Exhibit 3 . Alnylam agrees to con sider such a request in good faith, but shall not be obli gated to expand the definition of GalNac Process Te chnology to include such improvements . ” 4 2.7 Section 1.51 of Exhibit 1 of the Amended Licens e Agreement shall be deleted and replaced in its en tirety by the following : means, with respect to a Licensor, all Know - How C ontrolled by such Licensor on the Effective Date or during the term of this Agreement ( except as otherwise expressly provided herein ) th at relates to ( a ) miRNA Compounds or miRNA Therapeutics in gen eral, ( b ) specific miRNA Compounds or miRNA Therapeutics, ( c ) chemistry or delivery of miRNA Co mpounds or miRNA Therapeutics, ( d ) mechanism(s ) of action by which a miRNA Antagonist directly prevent s the production of a specific miRNA, or ( e ) method s of treating an Indication by modulating one or more mi RNAs ; provided, however, that in each case, ( i ) for any such Know - How that include financial or other obligation s to a Third Party, the provisions of Section 2.4 w ill govern whether such Know - How will be included as Licensed Know - How and ( ii ) Licensed Know How does not include manufacturing technology ( including but not limited to analytical methods ), other than, in the case of Alnylam as Licensor, Know - How ( to the extent relate d to manufacturing technology ) included in the GalN ac Process Technology . ” 2.8 Section 1.52 of Exhibit 1 of the Amended Licens e Agreement shall be deleted and replaced in its en tirety by the following : means, with respect to a Licensor, ( A ) all Patent Rights Controlled by such Licensor on the Effective Date and listed on Schedule 2.2(A ), and ( B ) all Patent Rights Controlled by such Lice nsor during the term of this Agreement ( except as otherw ise expressly provided herein ) that claim ( a ) miRNA Compounds or miRNA Therapeutics in general, ( b ) spe cific miRNA Compounds or miRNA Therapeutics, ( c ) chemistry or delivery of miRNA Compounds or miRNA T herapeutics, ( d ) mechanism(s ) of action by which a miRNA Antagonist directly prevents the production o f the specific miRNA, or ( e ) methods of treating an Indication by modulating one or more miRNAs ; provid ed, however, that in each case, ( i ) for any such Pa tent Rights that include financial or other obligations to a Third Party, the provisions of Section 2.4 wil l govern whether such Patent Right will be included as a Lic ensed Patent Right and ( ii ) Licensed Patent Rights do not include manufacturing technology ( including but not limited to analytical methods ), other than, in the case of Alnylam as Licensor, Patent Rights ( to the extent c laiming manufacturing technology ) included in the G alNac Process Technology . ” 2.9 The Amended License Agreement is hereby amended by including as Exhibit 3 to the Amended License Agreement, the Exhibit 3 ( AlnylamGalNac Process Tec hnology ) attached hereto